| Literature DB >> 28184200 |
Zandra C Félix Garza1, Joerg Liebmann2, Matthias Born2, Peter A J Hilbers1, Natal A W van Riel1.
Abstract
Clinical investigations prove that blue light irradiation reduces the severity of psoriasis vulgaris. Nevertheless, the mechanisms involved in the management of this condition remain poorly defined. Despite the encouraging results of the clinical studies, no clear guidelines are specified in the literature for the irradiation scheme regime of blue light-based therapy for psoriasis. We investigated the underlying mechanism of blue light irradiation of psoriatic skin, and tested the hypothesis that regulation of proliferation is a key process. We implemented a mechanistic model of cellular epidermal dynamics to analyze whether a temporary decrease of keratinocytes hyper-proliferation can explain the outcome of phototherapy with blue light. Our results suggest that the main effect of blue light on keratinocytes impacts the proliferative cells. They show that the decrease in the keratinocytes proliferative capacity is sufficient to induce a transient decrease in the severity of psoriasis. To study the impact of the therapeutic regime on the efficacy of psoriasis treatment, we performed simulations for different combinations of the treatment parameters, i.e., length of treatment, fluence (also referred to as dose), and intensity. These simulations indicate that high efficacy is achieved by regimes with long duration and high fluence levels, regardless of the chosen intensity. Our modeling approach constitutes a framework for testing diverse hypotheses on the underlying mechanism of blue light-based phototherapy, and for designing effective strategies for the treatment of psoriasis.Entities:
Keywords: computational model; epidermis; inflammatory skin conditions; keratinocytes; phototherapy; visible light
Year: 2017 PMID: 28184200 PMCID: PMC5266737 DOI: 10.3389/fphys.2017.00028
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
Figure 1Schematic description of the mechanistic model for blue light treatment of psoriasis. (A) The model considers the 4 sub-layers of the epidermis, the 6 stages of differentiation for keratinocytes across the sub-layers. (B) BLISS accounts for the cellular processes of proliferation (γ), differentiation (k), apoptosis (β), and desquamation (α).
BLISS model parameterization.
| Growth capacity of stem cells | 4.5 × 103 mm−2 | Zhang et al., | |
| γ1hom | Minimal stem cell self-proliferation rate constant | 3.30 × 10−3 d−1 | Zhang et al., |
| k1shom | Minimal symmetric healthy stem cell division rate constant | 1.64 × 10−3 d−1 | Clayton et al., |
| k1ahom | Minimal asymmetric healthy stem cell division rate constant | 1.31 × 10−2 d−1 | Clayton et al., |
| γ2h | Healthy transit amplifying cells self-proliferation rate constant | 1.40 × 10−2 d−1 | Bauer et al., |
| k2sh | Healthy transit amplifying cells symmetric division rate constant | 1.73 × 10−2 d−1 | Bauer et al., |
| k2ah | Healthy transit amplifying cells asymmetric division rate constant | 1.38 × 10−1 d−1 | Bauer et al., |
| k3h | Healthy growth arrested to spinous cells differentiation rate constant | 2.16 × 10−1 d−1 | Bauer et al., |
| k4h | Healthy spinous to granular cells differentiation rate constant | 5.56 × 10−2 d−1 | Bauer et al., |
| k5h | Healthy granular cells to corneocytes differentiation rate constant | 1.11 × 10−1 d−1 | Bauer et al., |
| k−1h | Back conversion rate constant of healthy cells (transit amplifying to stem cells) | 1.00 × 10−6 d−1 | Zhang et al., |
| k−2h | Back conversion rate constant of healthy cells (growth arrested to transit amplifying cells) | 1.00 × 10−6 d−1 | Zhang et al., |
| ω | Maximum fold increase of stem cells proliferation rate | 100 | Heenen et al., |
| Stem cells proliferation rate regulation by transit amplifying cells | 3 | Zhang et al., | |
| AI | Epidermal apoptosis index for healthy skin | 0.12% | Bauer et al., |
| β1h | Apoptosis rate of healthy epidermal stem cells | 1.97 × 10−6 d−1 | Calculated as described by Equation 16 |
| β2h | Apoptosis rate of healthy transit amplifying cells | 2.08 × 10−5 d−1 | Calculated as described by Equation 16 |
| β3h | Apoptosis rate of healthy growth arrested cells | 2.60 × 10−4 d−1 | Calculated as described by Equation 16 |
| β4h | Apoptosis rate of healthy spinous cells | 6.68 × 10−5 d−1 | Calculated as described by equation 16 |
| β5h | Apoptosis rate of healthy granular cells | 1.33 × 10−4 d−1 | Calculated as described by Equation 16 |
| αh | Healthy corneocytes desquamation rate constant | 7.14 × 10−2 d−1 | Weinstein et al., |
| ρsc | Fold change of stem cells proliferation in psoriasis | 4 | Weinstein et al., |
| ρta | Fold change of transit amplifying cells proliferation in psoriasis | 4 | Weinstein et al., |
| ρtr | Fold change of psoriatic cells transit rate | 5 | Weatherhead et al., |
| ρde | Fold change of psoriatic corneocytes desquamation | 4 | Weinstein and Van Scott, |
| λ | Fold change of stem cells growth capacity in psoriasis | 3.5 | Heenen et al., |
| Kp | Maximum immune response rate | 6 | Zhang et al., |
| Ka | Half-activation of immune system by psoriatic stem cells density | 380 | Zhang et al., |
| γ1d | Diseased stem cell self-proliferation rate constant | 1.16 × 10−2 d−1 | Calculated as the product of γ1hom and ρsc |
| k1sd | Symmetric diseased stem cell division rate constant | 5.70 × 10−3 d−1 | Calculated as the product of k1shom and ρsc |
| k1ad | Asymmetric diseased stem cell division rate constant | 4.59 × 10−2 d−1 | Calculated as the product of k1shom and ρsc |
| γ2d | Diseased transit amplifying cells self-proliferation rate constant | 4.90 × 10−2 | Calculated as the product of γ2h and ρta |
| k2sd | Diseased transit amplifying cells symmetric division rate constant | 6.06 × 10−2 d−1 | Calculated as the product of k2sh and ρta |
| k2ad | Diseased transit amplifying cells asymmetric division rate constant | 4.83 × 10−1 d−1 | Calculated as the product of k2ah and ρta |
| k3d | Diseased growth arrested to spinous cells differentiation rate constant | 9.72 × 10−1 d−1 | Calculated as the product of k3h and ρtr |
| k4d | Diseased spinous to granular cells differentiation rate constant | 2.50 × 10−1 d−1 | Calculated as the product of k4h and ρtr |
| k5d | Diseased granular cells to corneocytes differentiation rate constant | 3.89 × 10−1 d−1 | Calculated as the product of k5h and ρtr |
| AI | Epidermal apoptosis index for psoriatic skin | 0.035% | Bauer et al., |
| β1d | Apoptosis rate of diseased epidermal stem cells | 2.01 × 10−6 d−1 | Calculated as described by Equation 17 |
| β2d | Apoptosis rate of diseased transit amplifying cells | 2.12 × 10−5 d−1 | Calculated as described by Equation 17 |
| β3d | Apoptosis rate of diseased growth arrested cells | 3.40 × 10−4 d−1 | Calculated as described by Equation 17 |
| β4d | Apoptosis rate of diseased spinous cells | 8.76 × 10−5 d−1 | Calculated as described by Equation 17 |
| β5d | Apoptosis rate of diseased granular cells | 1.36 × 10−4 d−1 | Calculated as described by Equation 17 |
| αd | Diseased corneocytes desquamation rate constant | 2.50 × 10−1 d−1 | Calculated as the product of αh and ρde |
| aγ | Blue light coefficient for proliferation factor | 1 | Estimated from Liebmann et al., |
| bγ | Blue light coefficient for proliferation factor | −3.40 × 10−3 | Estimated from Liebmann et al., |
| ak | Blue light coefficient for differentiation factor | 2.46 | Estimated from Liebmann et al., |
| bk | Blue light coefficient for differentiation factor | 1.94 × 10−2 | Estimated from Liebmann et al., |
| ck | Blue light coefficient for differentiation factor | 3.46 | Estimated from Liebmann et al., |
| θ | Blue light factor increasing the apoptosis rate at fluences higher than 500 Jcm−2 and lower than 750 Jcm−2 | 3.9 × 10−2 | Awakowicz et al., |
| θ | Blue light factor increasing the apoptosis rate at fluences higher than 750 Jcm−2 | 5 × 10−2 | Awakowicz et al., |
| ξabs | Energy absorbance of the epidermis for a low perfused Caucasian skin | 57.9% | Calculated from optical model |
Blue light irradiation parameters.
| Fluence | 90 Jcm−2 |
| Irradiation mode | Continuous or pulsed |
| Irradiation time | 1800 s (30 min) |
| Duration of treatment | 84 days |
Initial cell density distribution (cells per mm.
| Corneocytes | 185 | 77,633 |
| Granular cells | 119 | 0 |
| Spinous cells | 238 | 79,788 |
| Growth arrested cells | 61 | 20,536 |
| Transit amplifying cells | 77 | 32,098 |
| Stem cells | 362 | 6459 |
| Total | 1042 + 216514 = 217,556 | |
Possible cases describing the blue light effects on the cellular processes of keratinocytes.
| 1 | Self-proliferation rates | θ | Proliferative cells, i.e. stem cells and |
| 2 | Asymmetric ( | θ | transit amplifying cells. |
| 3 | The self-proliferation rates ( | θ | |
| 4 | Asymmetric ( | θ | |
| 5 | Symmetric ( | θ | |
| 6 | The self-proliferation rates ( | θ | |
| 7 | The self-proliferation rates ( | θ | |
| 8 | Differentiation rates ( | θ | Non-proliferative cells, i.e. growth arrested cells, spinous cells, and granular cells. |
| 9 | Differentiation rates ( | θ | Proliferative cells, i.e. stem cells and transit amplifying cells. Non-proliferative |
| 10 | The self-proliferation rates ( | θ | cells, i.e. growth arrested cells, spinous cells, and granular cells. |
| 11 | The asymmetric division and differentiation rates ( | θ | |
| 12 | The symmetric division and differentiation rates ( | θ | |
| 13 | The self-proliferation rates ( | θ |
Figure 2Representing . The panels show the changes on the proliferation and differentiation of healthy and diseased keratinocytes due to different approaches of blue light in silico representation. Thirteen different cases are depicted in this figure. A detailed description of each case can be found in Table 4. These cases are grouped according to the parameters affected by blue light. Panels (A–G) show cases where only the proliferation and division parameters from the proliferative compartment are modified during blue light irradiation. Panel (H) presents the case where only the differentiation parameters from the non-proliferative compartment are affected. Panels (I–M) described the cases where blue light irradiation impacts both compartments. The upper plots of each panel show the impact of the blue light factor on the proliferation and differentiation rates of all keratinocyte populations as a consequence of the parameters affected by blue light. The lower panels display the impact of each potential representation on the proliferative (green), differentiation (blue), and immune system-cytotoxic (red) capacities.
Figure 3BLISS accurately describes The relative keratinocyte density is computed (solid black line) for irradiation schemes with fluences between 0 and 100 Jcm−2 and compared to the experimental data (Liebmann et al., 2010) of keratinocytes irradiated with three fluences of continuous wave blue light (gray dot). (B) The changes in the severity of a psoriasis lesion during (blue bar) and after treatment (black bar) are predicted (solid lines) for a pulsed wave treatment at high (red) and low (blue) intensities. These changes in the severity of the disease are shown in terms of the local psoriasis severity index (LPSI). The in silico results are compared to the clinical data (dots) of Pfaff et al. (2015).
Figure 4Multiple parameter sensitivity shows that variations in the proliferation parameters have a high impact on the final keratinocyte cell densities and the local severity of psoriasis at the end of treatment. (A) The sensitivity of healthy and diseased keratinocytes (x axis) to variations in the 58 model parameters (y axis) is depicted in the heat map. Only those with a Kolmogorov–Smirnov statistic value higher than 0.3 are shown in the y axis. (B) The sensitivity of the treatment outcome to changes in the same model parameters of Panel (A) are shown in the bar plot in terms of the local psoriasis severity index. Only those parameters with a Kolmogorov-Smirnov statistic value higher than 0.3 are shown in the x axis.
Figure 5Blue light induces a temporary reduction of all keratinocyte populations during the length of the treatment. (A) The time evolution of the healthy keratinocyte cell densities (dashed lines) comprised in a psoriatic epidermis are described during (blue bar) and after (black bar) blue light-based therapy. (B) Similarly, the time evolution of the diseased keratinocytes (continuous lines) is shown during and after treatment. Note the difference in scales of the y-axes between panels (A) and (B). In this simulation, the treatment periods divided into two sections. The first one consists of 28 days, with irradiation sessions occurring every day. The second section comprises 56 days, with treatment sessions happening three times per week. On each session a fluence of 90 Jcm−2 is applied for 30 min.
Figure 6The length of treatment is a key factor to achieve high treatment efficacy. (A) The LPSI at the end of treatment is predicted for treatment protocols with a total duration of 4–28 weeks. The treatment sessions in the simulated protocols occur either on a daily (blue dots) or every other day (green dots) basis. (B) A 12 weeks treatment with fluence of 90 Jcm−2 is simulated for continuous (black) and pulsed irradiation with low (blue) and high (red) peak intensities. (C) The variation in the LPSI value is predicted for irradiation schemes with low and high intensities of continuous wave blue light. (D) The evolution of the total keratinocyte cell densities during (blue bar) and after (black bar) treatment are derived using the same low and high intensities of continuous wave blue light presented in panel (C).
Figure 7High fluences of blue light yield higher management of psoriasis than low fluences. (A) The LPSI over time is computed for a 12 weeks continuous wave treatment with an initial LPSI of 5.17 (Pfaff et al., 2015) using 11 fluences. (B) The behavior of the blue light factor θ and the proliferation rate are visualized as functions of the fluence. (C) The bi-stability of the model is evaluated in the logarithmic scale for a wide range of fluences in a phase diagram of healthy and diseased keratinocytes. Only fluences above 500 Jcm−2 yield a shift the dominant keratinocyte population and the phenotype of the skin. (D) Fluences below this level remain in the disease state.